Ahead of Alnylam's key heart disease readout, experts say Pfizer rival would be hard to displace

As a closely watched readout from Alnylam Pharmaceuticals' Amvuttra in the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM) is expected in a few weeks, experts suggested the RNA silencer may have a hard time challenging a Pfizer med.